Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336114 | 1.00 | MAPT (0.49) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL336756 | 0.98 | MAPT (0.50) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL7453394 | 0.98 | MAPT (0.50) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL8393831 | 0.95 | MAPT (0.49) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL9041381 | 0.95 | MAPT (0.49) | MAPTANPEPERAP2CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL31341457 | 0.95 | MAPT (0.49) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL13805262 | 0.90 | CXCR4 (0.44) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL13805263 | 0.90 | CXCR4 (0.47) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL16800520 | 0.87 | MAPT (0.47) | MAPTANPEPERAP2CHRM5CHRM3 | |
| SCHEMBL30811210 | 0.87 | MAPT (0.47) | MAPTANPEPERAP2CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399938-A2 | Peptide purification by means of hard metal ion affinity chromatography | Novo Nordisk A/S (DK) | 2011-12-28 | — | — | EP | claimed |
| EP-2412729-A2 | Peptide purification by means of hard metal ion affinity chromatography | Novo Nordisk A/S (DK) | 2012-02-01 | — | — | EP | disclosed |
| EP-2399938-A2 | Peptide purification by means of hard metal ion affinity chromatography | Novo Nordisk A/S (DK) | 2011-12-28 | — | — | EP | disclosed |
| US-20090143529-A1 | Peptide purification by means of hard metal ion affinity chromatography | HEARN MILTON THOMAS WILLIAM | 2009-06-04 | — | — | US | disclosed |
| US-20090143529-A1 | Peptide purification by means of hard metal ion affinity chromatography | HEARN MILTON THOMAS WILLIAM | 2009-06-04 | — | — | US | disclosed |
| EP-1689384-A4 | COMPLEXES OF CYCLIC POLYAZA CHELATORS WITH CATIONS OF ALKALINE EARTH METALS FOR ENHANCED BIOLOGICAL ACTIVITY | CONCAT LP (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-2011501-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use | Chelator LLC (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1261349-B1 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE | CHELATOR LLC (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1758677-A2 | PEPTIDE PURIFICATION BY MEANS OF HARD METAL ION AFFINITY CHROMATOGRAPHY | NOVO NORDISK A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| EP-1689384-A1 | COMPLEXES OF CYCLIC POLYAZA CHELATORS WITH CATIONS OF ALKALINE EARTH METALS FOR ENHANCED BIOLOGICAL ACTIVITY | Concat LP (US) | 2006-08-16 | — | — | EP | disclosed |
| US-6165996-A | Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis | CONCAT, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0955044-A2 | Method of inhibiting bacterial or fungal growth using a complexing agent | CONCAT LTD. (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5874573-A | Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy | CONCAT, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0841951-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS, AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT LTD. (US) | 1998-05-20 | — | — | EP | disclosed |
| EP-0717639-A4 | POLYAMINO PARAMAGNETIC CHELATES WHICH CONTAIN BOTH PHOSPHONATE AND NON-PHOSPHONATE MOIETIES FOR MRI | CONCAT LTD (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997001360-A9 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | — | 1997-07-17 | — | — | WO | disclosed |
| WO-1997001360-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT, LTD. (US) | 1997-01-16 | — | — | WO | disclosed |
| EP-0717639-A1 | POLYAMINO PARAMAGNETIC CHELATES WHICH CONTAIN BOTH PHOSPHONATE AND NON-PHOSPHONATE MOIETIES FOR MRI | CONCAT LTD. (US) | 1996-06-26 | — | — | EP | disclosed |
| US-5409689-A | MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and non-phosphonate pendant arms | CONCAT, LTD. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1995005118-A1 | POLYAMINO PARAMAGNETIC CHELATES WHICH CONTAIN BOTH PHOSPHONATE AND NON-PHOSPHONATE MOIETIES FOR MRI | CONCAT LTD. (US) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143529-A1 | Peptide purification by means of hard metal ion affinity chromatography | MAX, PTMS, SLC7A1 | MAPT 2874/4885ANPEP 7/4885ERAP2 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.